FDA Clearance Tracker · P130026-S070
TactiCath Contact Force Ablation Catheter, Sensor Enabled
Last checked: Nov 20, 2026Latest source record: Nov 4, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Nov 4, 2021
Approved
Time to decision
217 days
Received Apr 1, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P130026-S070
- Device name
- TactiCath Contact Force Ablation Catheter, Sensor Enabled
- Applicant
- St Jude Medical
- Applicant location
- St. Paul, MN
- Received
- Apr 1, 2021
- Decided
- Nov 4, 2021
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P130026
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for the TactiCath Contact Force Ablation Catheter, Sensor Enabled. The device is indicated for use in cardiac electrophysiology mapping and for the treatment of drug refractory recurrent symptomatic, paroxysmal, and persistent atrial fibrillation, when used in conjunction with a compatible RF generator and three-dimensional mapping system.
Source documents
Other decisions for St Jude Medical
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K223077 · Decided Dec 7, 2022 · 68 days after receipt
Device type: Catheter, Ultrasound, Intravascular (OBJ) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.